Skip to content
π Tenofovir Alafenamide Fumarate (TAF) Tablet 25 mg
π Description:
- TAF is a prodrug of tenofovir, designed for enhanced delivery to target cells with lower systemic exposure.
- Each tablet contains 25 mg of tenofovir alafenamide fumarate, equivalent to tenofovir.
- The tablet is typically film-coated, and light yellow to beige in color.
- Itβs used primarily in the management of chronic hepatitis B virus (HBV) and HIV-1 infection.
- TAF is often preferred over older tenofovir forms due to its improved renal and bone safety.
πΏ Nature:
- TAF is a novel nucleotide reverse transcriptase inhibitor (NRTI).
- It is converted intracellularly to the active metabolite (tenofovir diphosphate) in target cells.
- Compared to tenofovir disoproxil fumarate (TDF), TAF requires lower dosing.
- It exhibits strong antiviral activity with minimal systemic toxicity.
- TAF is highly specific for the HBV and HIV reverse transcriptase enzyme.
β
Advantages:
- Lower risk of renal toxicity and bone mineral density loss compared to TDF.
- Effective at lower doses, making it safer and better tolerated.
- Once-daily dosing ensures ease of compliance.
- Can be co-formulated in fixed-dose combinations for HIV therapy.
- Approved for use in adolescents and adults with chronic HBV.
π©Ί Uses:
- Treatment of chronic hepatitis B infection in adults and adolescents aged β₯12 years.
- Component of combination antiretroviral therapy for HIV-1 infection.
- Used in patients with renal or bone issues where TDF is contraindicated.
- Preferred option in long-term antiviral therapy due to better safety.
- Sometimes used in HBV/HIV co-infected individuals.
βοΈ Storage:
- Store at room temperature between 20Β°C to 25Β°C (68Β°F to 77Β°F).
- Protect from moisture, heat, and direct sunlight.
- Keep the tablet in the original container with the desiccant.
- Do not refrigerate or freeze.
- Ensure the medicine is out of reach of children and check the expiration date before use.
Call Now Button